{"id":928122,"date":"2026-01-16T08:33:53","date_gmt":"2026-01-16T13:33:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\/"},"modified":"2026-01-16T08:33:53","modified_gmt":"2026-01-16T13:33:53","slug":"palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\/","title":{"rendered":"Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <i>PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative Colitis<\/i><br \/>\n        \n      <\/p>\n<p align=\"justify\">\n        <strong>Carlsbad, CA, Jan.  16, 2026  (GLOBE NEWSWIRE) &#8212; <\/strong>Palisade Bio, Inc. (Nasdaq: PALI) (\u201cPalisade\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that two abstracts highlighting its lead program, PALI-2108, have been selected for poster presentation at two premier international inflammatory bowel disease (IBD) meetings in early 2026.<\/p>\n<p align=\"justify\">Participation details are as follows:<\/p>\n<p align=\"justify\">\n        <b>Crohn\u2019s &amp; Colitis Congress<\/b><br \/>\n        <sup><br \/>\n          <b>\u00ae<\/b><br \/>\n        <\/sup><br \/>\n        <b> 2026<\/b><br \/>\n        <br \/>January 22\u201324, 2026 | Las Vegas, NV<\/p>\n<p align=\"justify\">\n        <b>Poster Presentation<\/b><br \/>\n        <br \/>\n        <b>Session:<\/b> Poster Hall Reception<br \/><b>Date &amp; Time:<\/b> Friday, January 23, 2026, 5:00 PM \u2013 6:30 PM PT<br \/><b>Title:<\/b> PALI-2108, a Colon-Targeted PDE4B Inhibitor, Rapidly Restores Immune-Epithelial Balance in Ulcerative Colitis Through Gut-Selective Lymphocyte Depletion<br \/><b>Presenter:<\/b> James Izanec, MD, AGAF, VP, Head of Clinical Development, Palisade Bio<\/p>\n<p align=\"justify\">\n        <b>21st Congress of ECCO \u2013 Inflammatory Bowel Diseases 2026<\/b><br \/>\n        <br \/>February 18\u201321, 2026 | Stockholm, Sweden<\/p>\n<p align=\"justify\">\n        <b>Poster Presentation<\/b><br \/>\n        <br \/>\n        <b>Session:<\/b> Guided Poster Session<br \/><b>Date &amp; Time:<\/b> Friday, February 20, 2026, 12:40 \u2013 13:40 CET<br \/><b>Location:<\/b> Poster Exhibition Hall A<br \/><b>Poster Number:<\/b> P0989<br \/><b>Title:<\/b> Gut-Targeted PDE4 Inhibition with PALI-2108 Demonstrates Rapid Clinical, Histologic, and Biomarker Improvement in Ulcerative Colitis: Translational Findings from a Phase 1a Study<br \/><b>Presenter: <\/b>James Izanec, MD, AGAF, VP, Head of Clinical Development, Palisade Bio<\/p>\n<p align=\"justify\">\u201cThese abstract acceptances underscore the growing scientific and clinical interest in PALI-2108 and its differentiated, gut-targeted approach to treating ulcerative colitis,\u201d said Dr. Mitchell Jones, Chief Medical Officer of Palisade Bio. \u201cWe look forward to engaging with the global IBD community and discussing these translational findings across two leading GI forums.\u201d<\/p>\n<p align=\"justify\">For more information about the congresses, please visit:<br \/>Crohn\u2019s &amp; Colitis Congress<sup>\u00ae<\/sup>: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=I2lxZHcGbqTu0C0IwVPwLusdgEOZU4xSr4snsVVJ1qsSl32BlhCitaq9WAh3Ge-yjyTp5RHXzkKOm1lKvxclExymqPw66FYKUDZl_vQV8E2Zf2O2lf4roAo_j-0fyWPk\" rel=\"nofollow\" target=\"_blank\">crohnscolitiscongress.org<\/a><br \/>ECCO Congress 2026: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CXBmiPGAtE627jWGACuZvTat6AFdTtjkcGL8t3iShwwUbkjmGaxv_WJFRPe3SRGekjL7f9QbidzJ2v-sBXiM8gSrgFXajrWu3sStD1iCu5S_6p26U1KaWAZ0R0Y2byNC6SXlNTK3r5elxJ5bhGOYXWVBnrobrM-llCfgvYzK7jI=\" rel=\"nofollow\" target=\"_blank\">ecco-ibd.eu\/ecco26\/our-congress\/overview<\/a><\/p>\n<p align=\"justify\">\n        <b>About PALI-2108<\/b>\n      <\/p>\n<p align=\"justify\">PALI-2108 is an orally administered, prodrug engineered for local delivery of phosphodiesterase-4 (PDE4) inhibition to the terminal ileum and colon. The prodrug molecule is gut-restricted and pharmacologically inactive until it reaches the lower intestine, where it is cleaved by bacterial enzymes to release its active PDE4 inhibitor metabolite directly at the site of inflammation and fibrosis. This targeted and slow-release design prevents absorption through the upper gut, achieves sustained local exposure and a longer half-life that enables once-daily dosing, and is engineered to produce a blunted peak plasma concentration to improve the overall therapeutic index. Together, these properties are intended to maximize anti-inflammatory and anti-fibrotic effects while minimizing systemic exposure and reducing class-related tolerability issues, such as nausea and headache, that have limited systemic PDE4 inhibitors.<\/p>\n<p align=\"justify\">\n        <b>About Palisade Bio<\/b>\n      <\/p>\n<p align=\"justify\">Palisade Bio, Inc. (Nasdaq: PALI) (\u201cPalisade\u201d or the \u201cCompany\u201d) is a clinical-stage biopharmaceutical company advancing a next generation oral PDE4 inhibitor prodrugs designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases.<\/p>\n<p align=\"justify\">The Company\u2019s lead program, PALI-2108, is a once-daily, ileum- and colon-targeted, locally bioactivated PDE4 inhibitor prodrug being developed for moderate-to-severe Ulcerative Colitis (UC) and fibrostenotic Crohn\u2019s Disease (FSCD), two diseases with limited non-immunosuppressive therapy options. In a recently reported Phase 1b trial, PALI-2108 achieved a 100% clinical response in the UC cohort, with no serious adverse events, favorable tolerability and pharmacokinetics consistent with localized activation in the lower intestine, low systemic exposure, and controlled release within the GI tract.<\/p>\n<p align=\"justify\">Palisade Bio is now advancing towards a Phase 2 clinical study in UC designed to evaluate clinical remission, response and pharmacodynamic biomarkers over 12 weeks, with an extension phase assessing maintenance of remission. In addition, the Company is preparing to initiate studies in FSCD to further characterize PALI-2108\u2019s safety, pharmacology and therapeutic benefit across inflammatory bowel disease indications. For more information, please go to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UkA1lkereQHFOPInTEqzMAK5cecxLEpm_rwRoJGtjZoUItBIEYVLCzyHoEfjOOE5A2CtTkC0V47JwobeL2SnAIgsKUu0MJ8slf2oDnyfrOo=\" rel=\"nofollow\" target=\"_blank\">www.palisadebio.com<\/a>.<\/p>\n<p align=\"justify\">\n        <b>Forward Looking Statements<\/b>\n      <\/p>\n<p align=\"justify\">Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to: statements regarding the timing and results of clinical trials, the potential mechanisms of action and therapeutic benefits of PALI-2108, and plans for regulatory submissions. These forward-looking statements are based on the Company\u2019s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company\u2019s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company\u2019s clinical trials; the Company\u2019s reliance on PALI-2108, and its early stage of clinical development; the risk that prior results, such as signals of safety, activity, dosing or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company\u2019s product candidates in clinical trials focused on the same or different indications; and other factors that are described in the \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d sections of the Company\u2019s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (\u201cSEC\u201d) on March 24, 2025, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company\u2019s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.<\/p>\n<p align=\"justify\">\n        <b>Investor Relations Contact<\/b>\n      <\/p>\n<p align=\"justify\">JTC Team, LLC<br \/>Jenene Thomas<br \/>908-824-0775<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HjSJ8JcgnyCR2bvNShO5qq4wKh334MvUtOBG_mN3ajUAAZVJfGcKhuX3WIKnTEZ9Cnk31GTD1f5mCP3U8wYGPA==\" rel=\"nofollow\" target=\"_blank\">PALI@jtcir.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNjc2MSM3MzY0NDk1IzUwMDEwOTEyMQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTIyZjIyODYtZTYxMi00ZjIxLWI4NjgtNjY1YWIwN2Y5YzUxLTUwMDEwOTEyMS0yMDI2LTAxLTE2LWVu\/tiny\/Palisade-Bio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative Colitis Carlsbad, CA, Jan. 16, 2026 (GLOBE NEWSWIRE) &#8212; Palisade Bio, Inc. (Nasdaq: PALI) (\u201cPalisade\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that two abstracts highlighting its lead program, PALI-2108, have been selected for poster presentation at two premier international inflammatory bowel disease (IBD) meetings in early 2026. Participation details are as follows: Crohn\u2019s &amp; Colitis Congress \u00ae 2026 January 22\u201324, 2026 | Las Vegas, NV Poster Presentation Session: Poster Hall ReceptionDate &amp; Time: Friday, January 23, 2026, 5:00 PM \u2013 6:30 PM PTTitle: PALI-2108, a Colon-Targeted PDE4B &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-928122","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative Colitis Carlsbad, CA, Jan. 16, 2026 (GLOBE NEWSWIRE) &#8212; Palisade Bio, Inc. (Nasdaq: PALI) (\u201cPalisade\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that two abstracts highlighting its lead program, PALI-2108, have been selected for poster presentation at two premier international inflammatory bowel disease (IBD) meetings in early 2026. Participation details are as follows: Crohn\u2019s &amp; Colitis Congress \u00ae 2026 January 22\u201324, 2026 | Las Vegas, NV Poster Presentation Session: Poster Hall ReceptionDate &amp; Time: Friday, January 23, 2026, 5:00 PM \u2013 6:30 PM PTTitle: PALI-2108, a Colon-Targeted PDE4B &hellip; Continue reading &quot;Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-16T13:33:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNjc2MSM3MzY0NDk1IzUwMDEwOTEyMQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences\",\"datePublished\":\"2026-01-16T13:33:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\\\/\"},\"wordCount\":971,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNjc2MSM3MzY0NDk1IzUwMDEwOTEyMQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\\\/\",\"name\":\"Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNjc2MSM3MzY0NDk1IzUwMDEwOTEyMQ==\",\"datePublished\":\"2026-01-16T13:33:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNjc2MSM3MzY0NDk1IzUwMDEwOTEyMQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNjc2MSM3MzY0NDk1IzUwMDEwOTEyMQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences - Market Newsdesk","og_description":"PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative Colitis Carlsbad, CA, Jan. 16, 2026 (GLOBE NEWSWIRE) &#8212; Palisade Bio, Inc. (Nasdaq: PALI) (\u201cPalisade\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that two abstracts highlighting its lead program, PALI-2108, have been selected for poster presentation at two premier international inflammatory bowel disease (IBD) meetings in early 2026. Participation details are as follows: Crohn\u2019s &amp; Colitis Congress \u00ae 2026 January 22\u201324, 2026 | Las Vegas, NV Poster Presentation Session: Poster Hall ReceptionDate &amp; Time: Friday, January 23, 2026, 5:00 PM \u2013 6:30 PM PTTitle: PALI-2108, a Colon-Targeted PDE4B &hellip; Continue reading \"Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-16T13:33:53+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNjc2MSM3MzY0NDk1IzUwMDEwOTEyMQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences","datePublished":"2026-01-16T13:33:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\/"},"wordCount":971,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNjc2MSM3MzY0NDk1IzUwMDEwOTEyMQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\/","name":"Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNjc2MSM3MzY0NDk1IzUwMDEwOTEyMQ==","datePublished":"2026-01-16T13:33:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNjc2MSM3MzY0NDk1IzUwMDEwOTEyMQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNjc2MSM3MzY0NDk1IzUwMDEwOTEyMQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-two-abstracts-selected-for-poster-presentations-at-leading-global-inflammatory-bowel-disease-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/928122","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=928122"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/928122\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=928122"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=928122"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=928122"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}